Fosun Pharma Starts China Phase III Trial of Long-Lasting Botox

Shanghai Fosun Pharma has started a China Phase III trial of its next-gen long-lasting Botox drug. It will test the drug as a therapy for glabellar (frown) lines and cervical dystonia (involuntary contraction of the neck muscles). In 2018, Fosun acquired rights to DaxibotulinumtoxinA from Revance Therapeutics of Nashville, TN in a $260 million deal. So far, Fosun has made a $30 million upfront payment. Revance has already concluded a successful US Phase III trial of the candidate as a treatment for glabellar lines. More details.... Stock Symbols: (SHA: 600196; HK: 02196) Share this with colleagues: // //